SCHEMBL7968637

SCHEMBL7968637

CCCCCCc1cccc(COc2ccc(/C=C3\SC(=S)NC3=O)cc2)c1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 2/20 0.67
MMP3 P08254 1/20 0.67
CTSD P07339 6/20 0.58
ADAMTS5 Q9UNA0 3/20 0.58
POLB P06746 3/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
BLM P54132 1/20 0.56
NOD2 Q9HC29 1/20 0.56
HPGD P15428 2/20 0.54
PTPN1 P18031 1/20 0.54
MAOA P21397 1/20 0.54
MAOB P27338 1/20 0.54
GPR35 Q9HC97 1/20 0.53
CISD1 Q9NZ45 1/20 0.52
PTGS2 P35354 1/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7968641 1.00 MMP13 (0.67) MMP13MMP3CTSDADAMTS5POLB
SCHEMBL7975149 0.92 MMP13 (0.72) MMP13MMP3CTSDADAMTS5POLB
SCHEMBL7975146 0.92 MMP13 (0.72) MMP13MMP3CTSDADAMTS5POLB
SCHEMBL7968931 0.90 MMP3 (0.69) MMP13MMP3CTSDADAMTS5POLB
SCHEMBL7968927 0.90 MMP3 (0.69) MMP13MMP3CTSDADAMTS5POLB
SCHEMBL4053583 0.89 MMP3 (0.71) MMP13MMP3CTSDADAMTS5POLB
SCHEMBL4049839 0.89 MMP3 (0.71) MMP13MMP3CTSDADAMTS5POLB
SCHEMBL7968119 0.86 MMP3 (0.72) MMP13MMP3CTSDADAMTS5POLB
SCHEMBL7968122 0.86 MMP3 (0.72) MMP13MMP3CTSDADAMTS5POLB
SCHEMBL7971922 0.84 MMP3 (0.64) MMP13MMP3CTSDPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6251928-B1 ADMINISTERING BENZYLIDENE RHODANINES WHICH ARE USEFUL AS AGENTS IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH BETA-AMYLOID PEPTIDE IN A MAMMAL ELI LILLY AND COMPANY 2001-06-26 US disclosed
EP-0677517-A1 Treatment of Alzheimer's disease employing inhibitors of cathepsin D ELI LILLY AND COMPANY (US) 1995-10-18 EP disclosed